{"pmid":32244017,"title":"Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment.","text":["Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment.","J Am Acad Dermatol","Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano","32244017"],"journal":"J Am Acad Dermatol","authors":["Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32244017","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaad.2020.03.057","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663079112866004992,"score":7.6048946,"similar":[{"pmid":32232551,"title":"COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence.","text":["COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence.","Rheumatol Int","Venerito, Vincenzo","Lopalco, Giuseppe","Iannone, Florenzo","32232551"],"journal":"Rheumatol Int","authors":["Venerito, Vincenzo","Lopalco, Giuseppe","Iannone, Florenzo"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232551","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s00296-020-04566-9","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662899337742516224,"score":54.88091},{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1662334544051699712,"score":54.789143},{"pmid":32108459,"title":"[Treatment strategies of Budd-Chiari syndrome during the epidemic period of 2019 coronavirus disease].","text":["[Treatment strategies of Budd-Chiari syndrome during the epidemic period of 2019 coronavirus disease].","Prevention and control about the situation of 2019 coronavirus disease (COVID-19) are grim at present. In addition to supporting the frontline actively, medical workers in general surgery spare no efforts in making good diagnosis and treatment of specialized diseases by optimizing treatment process, providing medical advice online, mastering indications of delayed operation and emergency operation reasonably, etc. Budd-Chiari syndrome is a complex disorder, and severity of the disease varies, serious cases can be life threatening. While fighting the epidemic, medical workers should also ensure the medical needs of patients. However, instead of continuing the traditional treatment, a new management system should be developed. Based on the characteristics of Budd-Chiari syndrome patients in China and our experience, we divide the patients into ordinary and critical cases, and treatment strategies suitable for the epidemic period of COVID-19 are put forward for reference and discussion by physicians.","Zhonghua Wai Ke Za Zhi","Li, L H","Zhang, G","Dang, X W","Li, L","32108459"],"abstract":["Prevention and control about the situation of 2019 coronavirus disease (COVID-19) are grim at present. In addition to supporting the frontline actively, medical workers in general surgery spare no efforts in making good diagnosis and treatment of specialized diseases by optimizing treatment process, providing medical advice online, mastering indications of delayed operation and emergency operation reasonably, etc. Budd-Chiari syndrome is a complex disorder, and severity of the disease varies, serious cases can be life threatening. While fighting the epidemic, medical workers should also ensure the medical needs of patients. However, instead of continuing the traditional treatment, a new management system should be developed. Based on the characteristics of Budd-Chiari syndrome patients in China and our experience, we divide the patients into ordinary and critical cases, and treatment strategies suitable for the epidemic period of COVID-19 are put forward for reference and discussion by physicians."],"journal":"Zhonghua Wai Ke Za Zhi","authors":["Li, L H","Zhang, G","Dang, X W","Li, L"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108459","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112139-20200221-00109","keywords":["2019 coronavirus disease","Budd-Chiari syndrome","Coronavirus infections","Critical cases","Novel coronavirus pneumonia"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544204791808,"score":48.336918},{"pmid":32174095,"title":"[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","text":["[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures.","Zhonghua Shao Shang Za Zhi","Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F","32174095"],"abstract":["The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174095","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn501120-20200307-00132","keywords":["Acute respiratory distress syndrome","Corona Virus Disease 2019","Cytokines","Immune system","Pulmonary fibrosis"],"source":"PubMed","locations":["China","Guangzhou","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663095625944662016,"score":46.95118},{"pmid":32212881,"pmcid":"PMC7117596","title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":["anti-CTLA-4","COVID-19","SARS-CoV-2","anti-PD-1","anti-PD-L1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663095625815687168,"score":45.83719}]}